Comparative persistence of human sewage-specific enterococcal bacteriophages in freshwater and seawater. Booncharoen N, Mongkolsuk S, Sirikanchana K. Appl Microbiol Biotechnol. 2018 Jul;102(14):6235-6246. doi: 10.1007/s00253-018-9079-1. Epub 2018 May 21.

28 Dec 2018
0
0

Comparative persistence of human sewage-specific enterococcal bacteriophages in freshwater and seawater.
Booncharoen N, Mongkolsuk S, Sirikanchana K.
Appl Microbiol Biotechnol. 2018 Jul;102(14):6235-6246. doi: 10.1007/s00253-018-9079-1. Epub 2018 May 21.

Tags

Share this

Related Posts

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours. Scarzello, A. J., Jiang, Q., Back, T., Dang, H., Hodge, D., Hanson, C., Subleski J, Weiss JM, Stauffer JK, Chaisaingmongkol J, Rabibhadana S, Ruchirawat M, Ortaldo J, Wang XW, Norris PS, Ware CF, Wiltrout, R. H. (2016). Gut, 65(10), 1765-1775.
01 Oct 2016
0

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours. Scarzello, A. J., Jiang, Q., Back, T., Dang, H., Hodge, D., Hanson, C., Subleski J, Weiss JM, Stauffer JK, Chaisaingmongkol J, Rabibhadana S, Ruchirawat M, Ortaldo J, Wang XW, Norris PS, Ware CF, Wiltrout, R. H. (2016). Gut, 65(10), 1765-1775.

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours. Scarzello, A. J., Jiang, Q., Back, T., Dang, H., Hodge, D., Hanson, C., Subleski J, Weiss JM, Stauffer JK, Chaisaingmongkol J, Rabibhadana S, Ruchirawat M, Ortaldo J, Wang XW, Norris PS, Ware CF, Wiltrout, R. H. (2016). Gut, 65(10), 1765-1775.
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More